We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Incidence and rate of low blood sugar events were reduced with Toujeo in the first 12 weeks compared to insulin degludec, and comparable from weeks 13-24 and the full 24-week study period.